The duo’s joint venture is for a 40GWh EV battery plant Location of the facility in the US is not yet decided
Amazon signs green hydrogen supply deal with Plug Power
Plug Power Inc has signed a deal with Amazon.com Inc to supply liquid green hydrogen, the companies said on Thursday, sending the hydrogen fuel cell maker's shares up over 12% in early trade.
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
Atai reports its Q2 2022 results, announces a new $175 million loan facility and streamlines its operations.
MindMed Board of Directors Approves Reverse Share Split
Mind Medicine announces a reverse share split of its common shares at a 1-15 ratio. Exchange symbols will remain the same but new CUSIP numbers will be assigned by the appropriate regulators.
COMPASS Pathways plc announces second quarter 2022 financial results and business highlights
Compass Pathways reports its Q2 2022 results. Preparing for its Phase 3 clinical trial for TRD. Net loss of $21.0 million. Cash (and equivalents) of $207.2 million.
Gold to be the standout metal for the rest of 2022
Following another 75-basis-point hike from the Federal Reserve, gold looks to be the standout metal in the second half of the year.
COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa
Compass Pathways announces the launch of a Phase II clinical trial using psilocybin-based COMP360 as a treatment for anorexia nervosa.
Red Light Holland to Acquire Two Wellness Shops in the Netherlands: SmartShop Utrecht and SmartShop OSS
Red Light Holland acquires two of the Netherlands premier shops for psychedelic truffles and wellness products.
Pasithea Therapeutics Awarded a Drug Development Research Grant
Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.
Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs
Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer
Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies
Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.
